• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.66% Nasdaq Up0.88%

    Alexza Pharmaceuticals Inc. (ALXA)

    -NasdaqCM
    0.59 Down 0.05(7.81%) May 2, 4:00PM EDT
    ProfileGet Profile for:
    Alexza Pharmaceuticals Inc.
    2091 Stierlin Court
    Mountain View, CA 94043
    United States - Map
    Phone: 650-944-7000
    Website: http://www.alexza.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:28

    Business Summary 

    Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. It offers ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company also engages in developing AZ-002 (Staccato alprazolam) for treating patients with acute repetitive seizures, as well as in Phase 2a study for patients with epilepsy; and AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. It has collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alexza Pharmaceuticals Inc.

    Key Executives 
     PayExercised
    Mr. Thomas B. King , 61
    Chief Exec. Officer, Pres, Principal Financial Officer, Principal Accounting Officer and Director
    778.00K0.00
    Dr. Edwin S. Kamemoto Ph.D., 62
    Exec. VP of R&D and Quality
    383.00K0.00
    Ms. Catherine McAuliffe ,
    VP of Operations
    N/AN/A
    Ms. Ana Kapor ,
    Sr. Director of Investor Relations and Corp. Communications
    N/AN/A
    Dr. Tatjana Naranda Ph.D.,
    VP of Bus. Devel. and Global Alliance Management
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders